European Journal of Molecular & Clinical Medicine

Abstract

Prostate cancer remains most mutual malignancy throughout males in India. DRE and PSA are commonly used for clinical and biochemical evaluation of suspected patients. TRUS is the main imaging modality aimed at both benign besides malignant disease. In view of limits of PSA, DRE as well as TRUS, MRI is the evolving modality. PIRADS refers to structured reporting scheme for evaluating prostate cancer. It is based on T2W and Diffusion weighted sequences along with Dynamic contrast enhanced scan which offers additional value for localisation of lesion. This research was carried out at an Eastern India regional health center, where 50 patients were in total. The research involved individuals with DRE offender, unfavorable TRUS controlled biopsy as well as high PSA. Most of the patients with PIRADS 4 and 5 came out to be proastatic adenocarcinoma showing high Gleason score in TRUS guided biopsy.